<DOC>
	<DOCNO>NCT00515021</DOCNO>
	<brief_summary>To determine nighttime administration aldosterone antagonist would effectively lower peak plasma PAI-1 level effectively morning administration .</brief_summary>
	<brief_title>Diurnal Variation Plasminogen Activator Inhibitor-1</brief_title>
	<detailed_description>Plasminogen activator inhibitor-1 , member serine protease inhibitor ( serpin ) superfamily , principal inhibitor tissue-type plasminogen activator urokinase-type plasminogen activator . Elevated plasma PAI-1 level , independent cardiovascular risk factor , show predictor recurrent myocardial infarction ( MI ) . Acute change plasma PAI-1 MI predictor mortality . PAI-1 level elevate individual hypertension , insulin resistance , hypertriglyceridemia , obesity , constellation risk-factors know metabolic syndrome . PAI-1 synthesize liver , vascular endothelium , vascular smooth muscle , visceral adipose tissue . A number factor show regulate PAI-1 , include metabolic factor insulin , glucose , triglyceride ; inflammatory cytokine tumor necrosis factor-α , transform growth factor-β , interleukin-1 , notably , component RAAS , namely angiotensin II aldosterone . PAI-1 also diurnal variation peak plasma level occur 8 9 AM may help explain incidence acute MI high morning thrombolysis least effective time . PAI-1 's diurnal variation show directly regulate central peripheral circadian pacemaker vitro , vivo . Our group observe diurnal variation plasma PAI-1 level blunt delay blind individual 's circadian mechanism free running ( controlled central circadian pacemaker ) compare whose circadian rhythm entrain ( controlled central circadian pacemaker ) ( unpublished data ) , suggest additional system may modulate diurnal variation PAI-1 . As PRA aldosterone level peak early PAI-1 level , may partially responsible . Indeed , continuous infusion candesartan eliminate diurnal variation aortic PAI-1 message expression Wistar-Kyoto spontaneously hypertensive rat , hydralazine . The use therapy modulate plasma PAI-1 level human subject meet variable success . Low salt diet show increase plasma PAI-1 level normotensive subject manner correlate plasma aldosterone level . Twice daily treatment quinapril ( 40mg ) lower plasma PAI-1 level expect peak time . In second study twice daily quinapril compare twice daily losartan normotensive subject modest effect plasma PAI-1 level . A third study help explain find . In crossover study , hypertensive subject receive daily spironolactone hydrochlorothiazide ( HCTZ ) randomize fashion . Plasma PAI-1 level increase HCTZ treatment , significantly change baseline spironolactone treatment . Spironolactone treatment , however , result significantly high aldosterone level . The correlation plasma aldosterone PAI-1 observe baseline HCTZ treatment observe spironolactone arm , suggest endogenous relationship aldosterone PAI-1 disrupt mineralocorticoid receptor antagonism .</detailed_description>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Plasminogen Activator Inhibitor 1</mesh_term>
	<mesh_term>Plasminogen Inactivators</mesh_term>
	<criteria>Age1865 Metabolic Syndrome ( 3 follow ) : 1 . Blood pressure 130/85 great 2 . Central obesity ( Waist Male &gt; 40 '' , Female &gt; 35 '' ) 3 . Fasting glucose ≥ 110 mg/dl 4 . Low HDL ( Male &lt; 40 mg/dl , Female &lt; 50 mg/dl ) 5 . Elevated Triglycerides ( &gt; 150 mg/dl ) Cigarette Use Renal insufficiency Coronary Artery Disease Diabetes Blindness Cerebrovascular Disease Secondary hypertension ( renal artery stenosis , pheo , etc . ) RAAS disease ( Primary Aldosteronism , etc . ) Other chronic illness ( cancer , autoimmune liver disease ) Pregnancy Anemia ( Hgb &lt; 12 mg/dl ) Evening Night Shift work Transmeridian travel previous 6 month History sleep disorder Hypokalemia ( serum potassium &lt; 3.5 mEq/L ) Hyperkalemia ( serum potassium &gt; 5.5 mEq/L ) Reported hypersensitivity HCTZ eplerenone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Aldosterone inhibitor</keyword>
	<keyword>Diurnal drug regimen</keyword>
	<keyword>PAI-1 level</keyword>
</DOC>